Organization
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
3 abstracts
Abstract
First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma.Org: Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Medical Oncology Department, Hospital Universitario 12 De Octubre, Hospital Clinic of Barcelona, Hospital Clinic i Provincial de Barcelona,
Abstract
Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).Org: Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain, Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Hospital Clínic de Barcelona, Barcelona, Spain, Hospital Clínic Barcelona, Barcelona, Spain, Hospital Clinic de Barcelona, Barcelona, Spain,
Abstract
ASSOCIATION STUDY OF GENETIC RISK VARIANTS FOR PSORIASIS IN A LARGE COHORT OF PSORIATIC ARTHRITIS, PSORIASIS AND CONTROLS OF THE SPANISH POPULATION AND ASSOCIATION WITH RELEVANT CLINICAL SUBPHENOTYPES Org: Hospital Clinic i Provincial de Barcelona, Barcelona, Spain, Hospital Universitario Gregorio Marañόn, Madrid, Complejo Hospitalario Juan Canalejo, A Coruña, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, Hospital Universitario de Salamanca, Salamanca,